

Reversed Halo Sign: A Systematic Review

Venkata N Maturu MD and Ritesh Agarwal MD DM

A reversed halo sign (RHS) is defined as the presence of a focal ring-shaped area of ground-glass opacity within a peripheral rim of consolidation. Although originally described in patients with cryptogenic organizing pneumonia, it has been described with several other noninfectious and infectious diseases, including fungal infections. Thus, it is imperative that a proper diagnosis be established before initiating treatment. In this article, we systematically review the literature (PubMed and Embase) for the associations of the RHS. We have also proposed a diagnostic algorithm for an approach to a patient with an RHS. Key words: reversed halo sign; RHS; computed tomography; HRCT; MDCT; Aspergillus; mucormycosis. [Respir Care 2014;59(9):1440–1449. © 2014 Daedalus Enterprises]

Introduction

The presence of central annular ground-glass opacity surrounded by a peripheral rim of consolidation, the so-called reversed halo sign (RHS), was first described in patients with cryptogenic organizing pneumonia¹ and was considered fairly specific for this disease.² Subsequently, several case reports and case series have reported the occurrence of the RHS in several other diseases (both infectious and noninfectious), thereby questioning the specificity of this sign. In this article, we systematically review the literature for the association of the RHS with various disorders. Furthermore, we also provide an algorithmic approach for a patient presenting with an RHS.

Methods

We first searched the PubMed and Embase databases for any systematic review reporting the association of the

RHS with various diseases. Only narrative reviews were found. We then independently searched the PubMed and Embase databases (January 1993 to November 2013) using the following free text terms: “reversed halo sign” OR “reverse halo sign” OR “atoll sign” OR “fairy ring sign” without any language restriction (Fig. 1). We included studies (case reports and original articles) describing the association of the RHS with various diseases. We excluded editorials and reviews. Any disagreement was resolved by discussion between the authors. The database created from the electronic searches was compiled in a reference manager package (EndNote X7, Thomson Reuters, Philadelphia, Pennsylvania), and all duplicate citations were eliminated. The citations were first screened by both authors to capture relevant studies. The full text of each citation was then obtained and reviewed in detail.

Data were recorded on a standard data extraction form. The following items were extracted: (1) publication details (title, authors, and other citation details), including country where the study was conducted; (2) patient demographics (age, sex, and immune status of the patient); and (3) modality used for establishing the diagnosis.

An institutional review board clearance was not required for this study, as this was a systematic review of published studies.

Results

Our initial database search yielded 94 citations, of which 58 case reports or case series (209 patients with an RHS) were included in the final review (Table 1).^{1–58} The RHS

The authors are affiliated with the Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

The authors have disclosed no conflicts of interest.

Correspondence: Ritesh Agarwal MD DM, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. E-mail: riteshpgi@gmail.com, agarwal.ritesh@pgimer.edu.in.

DOI: 10.4187/respcare.03020




Fig. 1. Citation selection process for systematic review.

has been demonstrated to be present in several diseases, infectious as well as noninfectious (Table 2). The largest case series was published by Marchiori et al⁴⁶ and included 79 patients.

Infectious Diseases

The RHS is most commonly associated with invasive fungal infections, most commonly with mucormycosis (see Table 2). It has not been described in candidiasis or fusariosis. All the case reports of invasive fungal infections with an RHS are in immunocompromised hosts (hematologic malignancies, diabetes mellitus, and post-chemotherapy state). The RHS has also been described in endemic infections such as paracoccidioidomycosis and tuberculosis. In invasive fungal infection complicating immunosuppressed individuals, the sign appears as one or more large lesions, whereas in endemic mycoses, the lesions are bilateral and asymmetric, associated with ground-glass opacities, centrilobular nodules, or areas of consolidation.^{8,41} Other infections where it is uncommonly seen are histoplasmosis, cryptococcosis, influenza, psittacosis, *Pneumocystis*, and *Legionella* pneumonia. In patients with pneumococcal pneumonia, the RHS has been seen in the resolution phase and thus represents a post-infectious organizing pneumonia.³³

Noninfectious Diseases

The RHS was first described in cryptogenic organizing pneumonia, and this sign is most commonly associated

with this condition. The RHS has been described in organizing pneumonia secondary to various causes (see Table 1). Other noninfectious diseases associated with the RHS are sarcoidosis, vasculitis, and a cellular variant of non-specific interstitial pneumonia. Another important condition associated with the RHS is pulmonary thromboembolism,^{46,49} where the diagnosis would be based on clinicroadiologic grounds. There are also case reports of association with other diseases such as lipid pneumonia, lymphomatoid granulomatosis, lymphocytic interstitial pneumonia, tuberous sclerosis complex, hypersensitivity pneumonia, and bronchoalveolar carcinoma.

Histopathologic Correlation of the RHS

The first pathologic description of the RHS was given by Voloudaki et al¹ in cryptogenic organizing pneumonia. The central ground-glass opacity was due to alveolar septal inflammation with intact alveolar air spaces. The denser rim was due to inflammation/granulation tissue within the air space itself. A similar pathologic description has also been provided in other reports.^{6,8,54} In all the aforementioned cases, the central ground-glass area had only alveolar septal inflammation, whereas the denser rim was composed of intra-alveolar infiltrate. However, in invasive fungal infections, the RHS is due to infarct, with greater hemorrhage at the periphery than in the center.²⁰ The central infarct may show multiple levels of pulmonary arteries and veins extensively occluded by thrombi containing numerous *Zygomycetes* hyphae. In the peripheral ring, inflammation, massive hemorrhage, and fibrinous exudates were noted.⁴⁵ In a patient with tumor emboli, the RHS lesion at autopsy was composed of central necrotic islands surrounded by a peripheral ring-like hemorrhagic band. The pulmonary vasculature and lymphatics near the hemorrhagic band were occluded by tumor emboli.⁵² In lymphomatoid granulomatosis, the central ground-glass opacity is due to central necrosis, whereas the peripheral rim is due to the angioinvasive nature of lymphomatoid granulomatosis.¹⁴ Thus, a similar computed tomography (CT) appearance of the RHS may occur due to differing pathological processes. In angioinvasive fungal infections (and possibly in pulmonary thromboembolism), the central ground-glass opacity is due to infarct with preserved air spaces, whereas in organizing pneumonia, the central ground-glass opacity is due to inflammation of the alveolar septa alone. The rim of consolidation is due to dense inflammation, granulation tissue, or hemorrhage within the alveolar air spaces.

Discussion

The CT appearance of central ground-glass opacity within a ring- or crescent-shaped rim of consolidation (Fig.

Table 1. Details of Publications Reporting the Reversed Halo Sign

Reference	Country	Final Diagnosis	Patients (n)	Age (y)	Sex (Male/Female)	Basis for Diagnosis	Immune Status
Voloudaki et al ¹	Greece	COP	2	50–53	1/1	Histopathology (SLB)	Immunocompetent
Marlow et al ³	USA	Sarcoidosis	1	43	0/1	Histopathology (TBLB)	Immunocompetent
Zompatori et al ⁴	Italy	COP	1	58	0/1	Histopathology (TBLB)	Immunocompetent
Kondo et al ⁵	Japan	Secondary OP (minocycline-induced)	1	39	0/1	Histopathology (TBLB)	Immunocompetent
Fujii et al ⁶	Japan	Sarcoidosis with secondary OP	1	40	1/0	Histopathology (SLB)	Immunocompetent
Choi et al ⁷	Korea	Small vessel vasculitis	1	41	0/1	Histopathology (VATS lung biopsy)	Immunocompetent
Kim et al ²	Korea	COP	6	20–79	NA	Histopathology	Immunocompetent
Gasparetto et al ⁸	Brazil	Pulmonary paracoccidioidomycosis	15	20–58	13/2	BAL, bronchial or transbronchial lung biopsy	NA
Hata and Uehara ⁹	Japan	Secondary OP (drug-related: Sho-sheriyu-to, an herbal medicine)	1	67	1/0	Radiologic finding and response to steroids and withdrawal of drug	Immunocompetent
Soberón et al ¹⁰	Spain	Organizing pneumonia: cryptogenic in 2 patients, secondary OP in 2 patients	4	22–87	NA	Histopathology	Immunocompetent
Agarwal et al ¹¹	India	GPA	1	28	1/0	C-ANCA positivity and renal biopsy suggestive of crescentic glomerulonephritis	Immunocompetent
Ahuja et al ¹²	India	Tuberculosis	1	15	1/0	Acid fast bacilli positive on VATS lung biopsy	Immunocompetent
Arai et al ¹³	Japan	COP	1	56	0/1	Histopathology (TBLB)	Immunocompetent
Benamore et al ¹⁴	Canada	Lymphomatoid granulomatosis	1	50	0/1	Histopathology (SLB)	Immunocompetent
Hsu et al ¹⁵	NA	Secondary OP (chronic lymphocytic leukemia)	1	54	1/0	Histopathology (needle aspiration)	Immunocompetent
Kanaji et al ¹⁶	Japan	Exogenous lipid pneumonia	1	50	1/0	Histopathology (VATS lung biopsy)	Immunocompetent
Okubo et al ¹⁷	Japan	Psittacosis	1	52	0/1	Elevated antibody against <i>Chlamydia psittaci</i> and response to minocycline	Immunocompetent
Sakai et al ¹⁸	Japan	<i>Legionella pneumophila</i> pneumonia	2	27–91	NA	Microbiological evidence	NA
Ueda et al ¹⁹	Japan	Idiopathic nonspecific interstitial pneumonia	1	39	1/0	Histopathology (VATS lung biopsy)	Immunocompetent
Wahba et al ²⁰	Texas	Mucormycosis Invasive aspergillosis	7 1	24–70	5/3	BAL (4 patients) TTNA (2 patients) TBLB (1 patient) Lobectomy (1 patient)	Immunocompromised
Bräunlich et al ²¹	Germany	Lymphomatoid granulomatosis	1	79	1/0	Histopathology (SLB)	Immunocompetent
Kumazoe et al ²²	Japan	Sarcoidosis	1	27	1/0	Histopathology (TBLB)	Immunocompetent
Tzouveleakis et al ²³	Greece	Acute fibrinous and OP	1	65	0/1	Histopathology (VATS lung biopsy)	Immunocompetent
Burke et al ²⁴	UK	COP	1	40	0/1	Radiologic evidence and response to steroids	Immunocompetent

(continued)

Table 1. Continued

Reference	Country	Final Diagnosis	Patients (n)	Age (y)	Sex (Male/Female)	Basis for Diagnosis	Immune Status
Chung et al ²⁵	USA	Pulmonary mucormycosis	1	64	0/1	Histopathology (CT-guided biopsy)	Immunocompromised (post-HSCT, diabetes)
Godbert et al ²⁶	France	COP	1	51	0/1	Clinicoradiologic evidence and response to steroids	Immunocompetent
Ito et al ²⁷	Japan	Secondary OP (bird fancier's lung)	1	70	1/0	Exposure to pigeons, antibody positivity, and histopathology (SLB)	Immunocompetent
Maimon ²⁸	Canada	COP	1	47	0/1	Histopathology (SLB)	Immunocompetent
Marchiori et al ²⁹	Brazil	Tuberculosis	1	32	0/1	Sputum smear positivity and histopathology (SLB)	Immunocompetent
Marchiori ³⁰	Brazil	Sarcoidosis	1	44	0/1	Histopathology (SLB)	Immunocompetent
Otera et al ³¹	Japan	<i>Pneumocystis</i> pneumonia	1	32	1/0	Microbiologic evidence on lung biopsy	Immunocompromised (AIDS)
Tokuyasu et al ³²	Japan	Secondary OP (dermatomyositis)	1	55	0/1	Histopathology (VATS lung biopsy)	Immunocompetent
Tzilas et al ³³	Greece	Secondary OP (pneumococcal pneumonia)	1	57	0/1	Urinary antigen positivity and response to moxifloxacin	Immunocompetent
Walsh and Robertson ³⁴	UK	COP	1	NA	1/0	Histopathology (SLB)	Immunocompetent
Anai et al ³⁵	Japan	Secondary OP (Sjogren syndrome)	1	41	0/1	SS-A positivity and histopathology (TBLB and lip biopsy)	Immunocompetent
Godoy and Marom ³⁶	USA	Pulmonary mucormycosis	1	24	0/1	Microbiologic evidence (TBLB)	Immunocompromised (acute myeloid leukemia chemotherapy)
Gudavalli et al ³⁷	USA	Secondary OP (post-irradiation)	2	65, 71	0/2	Histopathology (TBLB)	Immunocompetent
Hong et al ³⁸	Korea	Idiopathic nonspecific interstitial pneumonia	1	52	0/1	Histopathology (VATS lung biopsy)	Immunocompetent
Inoue et al ³⁹	Japan	COP	7	46-73	4/3	Histopathology (TBLB)	Immunocompetent
Mango et al ⁴⁰	USA	Post-RFA (likely secondary OP)	1	80	1/0	History of RFA and spontaneous resolution	Immunocompetent
Marchiori et al ⁴¹	Brazil	Pulmonary histoplasmosis	1	23	1/0	Microbiologic evidence (BAL)	Immunocompetent
Mehta et al ⁴²	USA	COP	1	54	0/1	Histopathology (TBLB)	Immunocompetent
Mukai et al ⁴³	Japan	Secondary OP (post-radiation)	1	69	0/1	Histopathology (TBLB)	Immunocompetent
Busca et al ⁴⁴	Italy	Pulmonary mucormycosis	1	55	0/1	Microbiologic evidence (TBLB)	Immunocompromised (post-HSCT)
Kimura et al ⁴⁵	Japan	<i>Cunninghamella</i> pneumonia	1	53	0/1	Histopathology (postmortem lung biopsy)	Immunocompromised (post-HSCT)

(continued)

Table 1. Continued

Reference	Country	Final Diagnosis	Patients (n)	Age (y)	Sex (Male/Female)	Basis for Diagnosis	Immune Status
Marchiori et al ⁴⁶	Brazil	Organizing pneumonia: 18; paracoccidioidomycosis: 12; aspergillosis: 6; mucormycosis: 6; tuberculosis: 12; cryptococcosis: 1; histoplasmosis: 1; pulmonary embolism: 7; sarcoidosis: 5; GPA: 2; pulmonary edema: 3; bronchoalveolar carcinoma: 3; <i>Pneumocystis jirovecii</i> pneumonia, 1	79	21–77	44/35	Varied	NA
Markos et al ⁴⁷	USA	Secondary OP (cutaneous T-cell lymphoma)	1	53	0/1	Histopathology (VATS lung biopsy)	Immunocompetent
Valente et al ⁴⁸	Italy	H1N1 pneumonia and ARDS	3	21–76	NA	RT-PCR positivity	Immunocompetent
Casullo and Semionov ⁴⁹	Canada	Pulmonary thromboembolism	12	21–80	5/7	Computed tomography pulmonary angiography (11 patients), multidetector-row computed tomography (1 patient)	Immunocompetent
Choo et al ⁵⁰	Korea	Mucormycosis	2	43, 47	2/0	Histopathology	Immunosuppressed
Freeman et al ⁵¹	USA	Lymphocytic interstitial pneumonia	1	52	0/1	Histopathology (CT-guided biopsy)	Immunocompetent
Goshima et al ⁵²	Japan	Pulmonary infarct (tumor emboli)	1	79	0/1	Postmortem lung biopsy	Immunocompetent
Madan and Guleria ⁵³	India	COP	1	14	0/1	Histopathology (CT-guided biopsy)	Immunocompetent
Okubo et al ⁵⁴	Japan	Mucormycosis	1	64	1/0	Histopathology (lobectomy)	Immunocompromised (acute lymphoblastic leukemia chemotherapy)
Stewart et al ⁵⁵	USA	Mucormycosis	1	63	0/1	Histopathology (TBLB)	Immunocompromised (renal transplant)
Suzuki et al ⁵⁶	Japan	Tuberous sclerosis complex	1	NA	0/1	CT-guided TTNA	Immunocompetent
Yüksekkaya et al ⁵⁷	Turkey	Hypersensitivity pneumonitis	1	54	1/0	Histopathology (VATS lung biopsy)	Immunocompetent
Zhan et al ⁵⁸	China	Tuberculosis	17	36 ± 14	7/10	Histopathology (CT-guided biopsy)	Immunocompetent

COP = cryptogenic organizing pneumonia
 SLB = surgical lung biopsy
 TBLB = transbronchial lung biopsy
 OP = organizing pneumonia
 VATS = video-assisted thoracoscopic surgery
 NA = not available
 BAL = bronchoalveolar lavage
 GPA = granulomatosis with polyangiitis
 C-ANCA = anti-neutrophil cytoplasmic antibody
 TTNA = transthoracic needle aspiration
 CT = computed tomography
 HSCT = hematopoietic stem cell transplant
 AIDS = acquired immune deficiency syndrome
 RFA = radiofrequency ablation
 RT-PCR = reverse transcription polymerase chain reaction

Table 2. Disorders Manifesting With the Reversed Halo Sign on Computed Tomography of the Chest

	No.
Infectious diseases	
Pulmonary mucormycosis ^{20,25,36,44,45,50,54,55,65}	23
Invasive pulmonary aspergillosis ^{20,65}	8
Histoplasmosis ⁴¹	1
Cryptococcosis ⁴⁶	1
Paracoccidioidomycosis ^{8,46}	27
<i>Pneumocystis jirovecii</i> pneumonia ^{31,46}	2
H1N1 ARDS ⁴⁸	3
Tuberculosis ^{12,46,58}	30
Psittacosis ¹⁷	1
<i>Legionella pneumophila</i> pneumonia ¹⁸	2
Noninfectious diseases	
Cryptogenic organizing pneumonia ^{1,2,4,10,13,23,24,26,28,34,39,53,65}	36
Secondary organizing pneumonia ^{5,6,9,10,15,27,32,33,35,37,40,43,47,65}	30
Vasculitis ^{7,11,46}	4
Sarcoidosis ^{3,22,46}	7
Lymphomatoid granulomatosis ^{14,21}	2
Idiopathic nonspecific interstitial pneumonia ^{19,38}	2
Lipoid pneumonia ¹⁶	1
Pulmonary thromboembolism ^{46,49}	19
Pulmonary tumor embolus ⁵²	1
Pulmonary edema ⁴⁶	3
Bronchoalveolar carcinoma ⁴⁶	3
Hypersensitivity pneumonitis ⁵⁷	1
Tuberous sclerosis complex ⁵⁶	1
Lymphocytic interstitial pneumonia ⁵¹	1
Total	209

2) was first described by Voloudaki et al¹ in two patients with cryptogenic organizing pneumonia. Similar descriptions of such ring or annular opacities were also provided by Kondo et al⁵ and Fujii et al,⁶ who described this pattern in patients with secondary organizing pneumonia. The term “reversed halo sign” was first used by Moon et al⁵⁹ when they described four patients with cryptogenic organizing pneumonia with this radiologic sign. Subsequently, the same group compared the CT findings of 31 patients with biopsy-proven cryptogenic organizing pneumonia with 30 patients without cryptogenic organizing pneumonia. The RHS was noted in 6 patients with cryptogenic organizing pneumonia (19%) and in none with other diseases.² The authors concluded that the presence of the RHS is a specific radiologic finding of cryptogenic organizing pneumonia.

The RHS was initially defined by Kim et al² as a central ground-glass opacity surrounded by a denser consolidation with a crescentic (forming more than three fourths of a circle) or ring (forming a complete circle) shape of at least 2 mm in thickness. This description was slightly modified by the Fleischner Society in 2008,⁶⁰ which describes the



Fig. 2. High-resolution computed tomography of the chest wall showing multiple areas with the reversed halo sign (arrows).

RHS as a focal rounded area of ground-glass opacity surrounded by a more or less complete ring of consolidation. This CT appearance has been variously described by different authors as reversed halo sign, reverse halo sign, atoll sign, or fairy ring sign. Even before the term RHS was coined, Zompatori et al⁴ used the term “atoll sign” to describe the same CT finding in 1999. The word atoll is derived from atholhu, a Maldivian word meaning an island consisting of a lagoon surrounded by a circular coral reef.

In 1999, Marlow et al³ used the term “fairy ring sign” in a patient with sarcoidosis to describe a ring-shaped opacity with normal appearing lung parenchyma in the center. The term “fairy ring” is derived from Gaelic mythology. Fairies would dance in small circles at night, and when tired, they would rest on the toadstools. The next day, one would see only a circle in the grass with a ring of mushrooms, which is described as a fairy ring. In a strict sense, the fairy ring sign differs from the RHS in that the center of the ring is normal appearing lung parenchyma in the former and ground-glass opacity in the latter. However, some authors tend to use the terms interchangeably, as the difference between the two is only minor, and both signs are seen in the same diseases. On occasion, the same chest CT may show both the fairy ring sign and the RHS.³⁴ As the terms atoll sign and fairy ring sign are not mentioned in the Fleischner glossary of radiologic terms, we suggest using the term RHS to describe this CT finding.

It was suggested previously that in an immunocompetent host, the presence of an RHS would be sufficient evidence for a trial of steroids and obviate the need for a lung biopsy.²⁶ As shown in the systematic review, the RHS is associated with a number of diseases, both infectious and noninfectious. In fact, the presence of the RHS in an immunocompromised host should be attributed to invasive fungal infection unless proven otherwise. The RHS




Fig. 3. Algorithmic approach for the reversed halo sign.

is also an early indicator of fungal infection, as it usually occurs within the first week of infection.⁶¹ In a study on sequential morphological changes in CT scan in pulmonary mucormycosis, it was shown that the halo sign and the RHS are the initial radiologic features. With treatment, they develop areas of central cavitation.⁵⁰ As opposed to the halo sign, which is more common with invasive aspergillosis, the RHS is most commonly seen with mucormycosis, and thus, its presence would indicate the need for a *Mucor*-specific antifungal agent such as amphotericin B or posaconazole.⁶² Also, it would be appropriate to rule out endemic infections such as paracoccidioidomycosis and tuberculosis depending on the patient's geographic location by appropriate investigations in patients presenting with RHS. To date, the RHS has not been described in typical community-acquired bacterial pneumonia, and hence, the presence of this sign should rule out a diagnosis of community-acquired pneumonia. With the growing number of diseases with which it is being associated, especially infectious causes, we would not recommend an empiric

steroid trial (as proposed earlier) without an attempt made to confirm the diagnosis.²⁶

Of the noninfectious causes of the RHS, the most commonly associated disease is organizing pneumonia. As the RHS can be encountered in both primary (cryptogenic organizing pneumonia) and secondary organizing pneumonia, it does not help in differentiating between cryptogenic and other causes. Thus, appropriate investigations should be carried out to rule out secondary causes (history of drugs, radiation exposure, connective tissue disease), which, if present, need to be treated simultaneously. Although many noninfectious diseases associated with the RHS (organizing pneumonia, hypersensitivity pneumonitis, sarcoidosis, vasculitis, cellular nonspecific interstitial pneumonia) might eventually need immunosuppression with steroids, it is important to confirm the diagnosis before starting therapy, as the degree and duration of immunosuppression needed in the individual disorders may vary. There are also reports of association with other rare diseases such as lipoid pneumonia, lymphomatoid granu-

lomatositis, and bronchoalveolar carcinoma, further underscoring the need for a lung biopsy.

Marchiori et al⁶³⁻⁶⁵ have proposed several radiologic criteria to distinguish various diseases based upon the morphologic appearance of the RHS on the CT scan. They propose that the presence of nodular walls or nodules within the lesion indicates granulomatous diseases such as tuberculosis and sarcoidosis rather than organizing pneumonia.^{63,64} Similarly, a greater thickness of the rim (>1 cm), the presence of reticulation within the rim of consolidation, and the presence of an associated pleural effusion point toward a fungal pneumonia rather than organizing pneumonia.⁶⁵

Clinical Approach to a Case with RHS

As the RHS is not specific for any disorder, we recommend an algorithmic approach as outlined in Figure 3. The overall clinical presentation needs to be considered while approaching a patient with RHS. In an immunocompromised host, amphotericin B should be initiated empirically for presumed invasive fungal infection, and further investigations should proceed depending on the clinical circumstances. In an immunocompetent host, we recommend lung biopsy wherever feasible before initiating treatment. Flexible bronchoscopy with bronchoalveolar lavage and lung biopsy should be the initial investigation, with CT-guided or surgical lung biopsy as alternative options. However, if a lung biopsy is not feasible, is contraindicated, or is inconclusive, focused noninvasive investigations should be performed as guided by the clinicoradiologic presentation of the patient to achieve a diagnosis. In countries endemic for tuberculosis or paracoccidioidomycosis, appropriate investigations have to be carried out to rule out these infections. Other investigations such as anti-neutrophil cytoplasmic antibody may be useful in the diagnosis of vasculitides. It is important to make a conclusive diagnosis before initiating treatment, as this sign is associated with both infectious and noninfectious diseases, for which the treatment approaches are totally differ. If lung biopsy and noninvasive investigations do not help in reaching a diagnosis, a trial of empiric steroids may be started once infections have been reasonably excluded.

Finally, our review is not without limitations. Although a systematic review, the data presented are a collection of case reports and case series, and hence, we cannot exclude publication and reporting biases.

Conclusions

The RHS, previously considered to be a hallmark of cryptogenic organizing pneumonia, can be encountered in a variety of pulmonary disorders, both infectious and non-infectious. The two most commonly associated diseases

are the organizing pneumonias and invasive fungal pneumonias (especially mucormycosis). As the treatment approach for these two diseases is diametrically opposite, we recommend obtaining a tissue diagnosis whenever feasible. The clinical presentation, immune status of the patient, and associated radiologic findings can help in narrowing down the differential diagnosis. In an immunocompromised host, antifungal therapy for mucormycosis should be initiated pending further investigations.

REFERENCES

- Voloudaki AE, Bouros DE, Froudarakis ME, Datsis GE, Apostolaki EG, Gourtsoyiannis NC. Crescentic and ring-shaped opacities. CT features in two cases of bronchiolitis obliterans organizing pneumonia (BOOP). *Acta Radiol* 1996;37(6):889-892.
- Kim SJ, Lee KS, Ryu YH, Yoon YC, Choe KO, Kim TS, Sung KJ. Reversed halo sign on high-resolution CT of cryptogenic organizing pneumonia: diagnostic implications. *AJR Am J Roentgenol* 2003; 180(5):1251-1254.
- Marlow TJ, Krapiva PI, Schabel SI, Judson MA. The "fairy ring": a new radiographic finding in sarcoidosis. *Chest* 1999;115(1):275-276.
- Zompatori M, Poletti V, Battista G, Diegoli M. Bronchiolitis obliterans with organizing pneumonia (BOOP), presenting as a ring-shaped opacity at HRCT (the atoll sign). A case report. *Radiol Med* 1999;97(4):308-310.
- Kondo H, Fujita J, Inoue T, Horiuchi N, Nakao K, Iwata M, et al. [Minocycline-induced pneumonitis presenting as multiple ring-shaped opacities on chest CT, pathologically diagnosed bronchiolitis obliterans organizing pneumonia (BOOP)]. *Nihon Kokyuki Gakkai Zasshi* 2001;39(3):215-219. *Article in Japanese*.
- Fujii M, Ida M, Enomoto N, Nogimura H, Nakamura Y, Chida K, Nakamura H. [A case of sarcoidosis manifesting as annular opacities after multiple nodular shadows]. *Nihon Kokyuki Gakkai Zasshi* 2002; 40(12):970-974. *Article in Japanese*.
- Choi YH, Im JG, Park CK. Notes from the 2001 Annual Meeting of the Korean Society of Thoracic Radiology. *J Thorac Imaging* 2002; 17(2):170-175.
- Gasparetto EL, Escuissato DL, Davaus T, de Cerqueira EM, Souza AS Jr, Marchiori E, Müller NL. Reversed halo sign in pulmonary paracoccidioidomycosis. *AJR Am J Roentgenol* 2005;184(6):1932-1934.
- Hata Y, Uehara H. [A case where herbal medicine sho-seiryu-to induced interstitial pneumonitis]. *Nihon Kokyuki Gakkai Zasshi* 2005; 43(1):23-31. *Article in Japanese*.
- Bravo Soberón A, Torres Sánchez MI, García Río F, Sánchez Almaraz C, Parrón Pajares M, Pardo Rodríguez M. [High-resolution computed tomography patterns of organizing pneumonia]. *Arch Bronconeumol* 2006;42(8):413-416. *Article in Spanish*.
- Agarwal R, Aggarwal AN, Gupta D. Another cause of reverse halo sign: Wegener's granulomatosis. *Br J Radiol* 2007;80(958):849-850.
- Ahuja A, Gothi D, Joshi JM. A 15-year-old boy with "reversed halo". *Indian J Chest Dis Allied Sci* 2007;49:99-101.
- Arai T, Inoue Y, Ando S, Inoue K, Tsuyuguchi K, Suzuki K, et al. [A case of cryptogenic organizing pneumonia showing reversed halo sign on computed tomography of the chest]. *Nihon Kokyuki Gakkai Zasshi* 2007;45(8):621-626. *Article in Japanese*.
- Benamore RE, Weisbrod GL, Hwang DM, Bailey DJ, Pierre AF, Lazar NM, Maimon N. Reversed halo sign in lymphomatoid granulomatosis. *Br J Radiol* 2007;80(956):e162-e166.

15. Hsu A, Stark P, Friedman PJ. Focal organizing pneumonia with reversed halo sign. *Appl Radiol* 2007;36:8.
16. Kanaji N, Bandoh S, Nagamura N, Soo Chang S, Ishikawa S, Yokomise H, et al. Lipoid pneumonia showing multiple pulmonary nodules and reversed halo sign. *Respir Med Extra* 2007;3(3):98-101.
17. Okubo T, Miyazaki E, Ueo M, Okubo F, Ando M, Fukami T, Kumamoto T. [A case of psittacosis with wandering infiltrates developing to acute respiratory distress syndrome]. *Nihon Kokyuki Gakkai Zasshi* 2007;45(5):419-423. *Article in Japanese.*
18. Sakai F, Tokuda H, Goto H, Tateda K, Johkoh T, Nakamura H, et al. Computed tomographic features of *Legionella pneumophila* pneumonia in 38 cases. *J Comput Assist Tomogr* 2007;31(1):125-131.
19. Ueda S, Inoue R, Tanaka K, Mizumori Y, Kawamura T, Nakahara Y, et al. [A case of nonspecific interstitial pneumonia with reversed halo sign on chest HRCT]. *Nihon Kokyuki Gakkai Zasshi* 2007;45(3):248-252. *Article in Japanese.*
20. Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. *Clin Infect Dis* 2008;46(11):1733-1737.
21. Bräunlich J, Seyfarth HJ, Gessner C, Gradistanac T, Wirtz H. Lymphomatoid granulomatosis: a short description of an unusual case of the disease. *Pneumologie* 2009;63(12):697-701.
22. Kumazoe H, Matsunaga K, Nagata N, Komori M, Wakamatsu K, Kajiki A, et al. "Reversed halo sign" of high-resolution computed tomography in pulmonary sarcoidosis. *J Thorac Imaging* 2009;24(1):66-68.
23. Tzouvelekis A, Koutsopoulos A, Oikonomou A, Froudarakis M, Zarogoulidis P, Steiropoulos P, et al. Acute fibrinous and organising pneumonia: a case report and review of the literature. *J Med Case Rep* 2009;3:74.
24. Burke L, Jacob BK. Reversed halo sign in cryptogenic organising pneumonia. *BMJ Case Rep* 2010. doi:10.1136/bcr.03.2010.2824
25. Chung JH, Godwin JD, Chien JW, Pipavath SJ. Case 160: pulmonary mucormycosis. *Radiology* 2010;256(2):667-670.
26. Godbert B, Clement-Duchêne C, Regent D, Martinet Y. [Do all cryptogenic organizing pneumonias require lung biopsy and steroid treatment?]. *Rev Mal Respir* 2010;27(5):509-514. *Article in French.*
27. Ito T, Sugino K, Satoh D, Muramatsu Y, Sano G, Sato K, et al. Bird fancier's lung which developed in a pigeon breeder presenting organizing pneumonia. *Intern Med* 2010;49(23):2605-2608.
28. Maimon N. A 47-year-old female with shortness of breath and "reversed halo sign". *Eur Respir Rev* 2010;19(115):83-85.
29. Marchiori E, Grando RD, Simões Dos Santos CE, Maffazzoli Santos Balzan L, Zanetti G, Mano CM, Gutierrez RS. Pulmonary tuberculosis associated with the reversed halo sign on high-resolution CT. *Br J Radiol* 2010;83(987):e58-60.
30. Marchiori E, Zanetti G, Mano CM, Hochhegger B, Irion KL. The reversed halo sign: another atypical manifestation of sarcoidosis. *Korean J Radiol* 2010;11(2):251-252.
31. Otera H, Tada K, Sakurai T, Hashimoto K, Ikeda A. Reversed halo sign in pneumocystis pneumonia: a case report. *BMC Med Imaging* 2010;10:26.
32. Tokuyasu H, Isowa N, Shimizu E, Yamadori I. Reversed halo sign associated with dermatomyositis. *Intern Med* 2010;49(15):1677-1678.
33. Tzilas V, Bastas A, Provata A, Koti A, Tzouda V, Tsoukalas G. The "reversed halo" sign in pneumonococcal pneumonia: a review with a case report. *Eur Rev Med Pharmacol Sci* 2010;14(5):481-486.
34. Walsh SL, Robertson BJ. Images in thorax. The atoll sign. *Thorax* 2010;65(11):1029-1030.
35. Anai S, Kumazoe H, Wakamatsu K, Nagata N, Nakanishi Y, Kajiki A. [Reversed halo sign in organizing pneumonia secondary to Sjogren syndrome]. *Nihon Kokyuki Gakkai Zasshi* 2011;49(9):707-712. *Article in Japanese.*
36. Godoy MCB, Marom EM. Reversed halo sign in pulmonary zygomycosis. *Thorax* 2011;66(6):544.
37. Gudavalli R, Diaz-Guzman E, Arrossi AV, Chapman JT, Mehta AC. Fleeting alveolar infiltrates and reversed halo sign in patients with breast cancer treated with tangential beam irradiation. *Chest* 2011;139(2):454-459.
38. Hong SH, Kang EY, Shin BK, Shim JJ. Reversed halo sign on thin-section CT in a patient with non-specific interstitial pneumonia. *Br J Radiol* 2011;84(1001):e103-e105.
39. Inoue Y, Yoshimura N, Shimada H, Saito H, Shimizu K, Kurata K, et al. [Clinical features of reversed halo sign in cryptogenic organizing pneumonia]. *Nihon Kokyuki Gakkai Zasshi* 2011;49(2):75-80. *Article in Japanese.*
40. Mango VL, Naidich DP, Godoy MCB. Reversed halo sign after radiofrequency ablation of a lung nodule. *J Thorac Imaging* 2011;26(4):W150-W152.
41. Marchiori E, Melo SM, Vianna FG, Melo BS, Melo SS, Zanetti G. Pulmonary histoplasmosis presenting with the reversed halo sign on high-resolution CT scan. *Chest* 2011;140(3):789-791.
42. Mehta H, Paoletti L, Pastis N, Judson M. Fairy ring sign on high resolution computed tomography in a patient with cryptogenic organizing pneumonia. *Chest* 2011;140(4):109A.
43. Mukai N, Tokuyasu H, Izumi H, Takeda K, Hikino H, Shimizu E. [A case of organizing pneumonia with a reversed halo sign following postoperative irradiation for breast cancer]. *Nihon Kokyuki Gakkai Zasshi* 2011;49(5):393-398. *Article in Japanese.*
44. Busca A, Limerutti G, Locatelli F, Barbui A, De Rosa FG, Falda M. The reversed halo sign as the initial radiographic sign of pulmonary zygomycosis. *Infection* 2012;40(1):77-80.
45. Kimura M, Araoka H, Uchida N, Ohno H, Miyazaki Y, Fujii T, et al. *Cunninghamella bertholletiae* pneumonia showing a reversed halo sign on chest computed tomography scan following cord blood transplantation. *Med Mycol* 2012;50(4):412-416.
46. Marchiori E, Zanetti G, Escuissato DL, Souza AS Jr., Meirelles GS, Fagundes J, et al. Reversed halo sign: high-resolution CT scan findings in 79 patients. *Chest* 2012;141(5):1260-1266.
47. Markos M, Takekoshi D, Joo M. Rare crescentic shaped radiographic findings of organizing pneumonia associated with cutaneous T-cell lymphoma. *Chest* 2012;142(4):554A.
48. Valente T, Lassandro F, Marino M, Squillante F, Aliperta M, Muto R. H1N1 pneumonia: our experience in 50 patients with a severe clinical course of novel swine-origin influenza A (H1N1) virus (S-OIV). *Radiol Med* 2012;117(2):165-184.
49. Casullo J, Semionov A. Reversed halo sign in acute pulmonary embolism and infarction. *Acta Radiol* 2013;54(5):505-510.
50. Choo JY, Park CM, Lee HJ, Lee CH, Goo JM, Im JG. Sequential morphological changes in follow-up CT of pulmonary mucormycosis. *Diagn Interv Radiol* 2014;20(1):42-46.
51. Freeman MD, Grajo JR, Karamsadkar ND, Steffensen TS, Hazelton TR. Reversed halo sign on computed tomography as a presentation of lymphocytic interstitial pneumonia. *J Radiol Case Rep* 2013;7(10):51-56.
52. Goshima H, Hiromi T, Nishio C, Fujii H, Katsuyama E. Reversed halo sign in pulmonary infarction with tumor emboli: a case report. *Respir Invest* 2013 [Epub ahead of print]. doi:10.1016/j.resinv.2013.08.004.
53. Madan K, Guleria R. Reverse halo sign. *Lung India* 2013;30(1):72-73.
54. Okubo Y, Ishiwatari T, Izumi H, Sato F, Aki K, Sasai D, et al. Pathophysiological implication of reversed CT halo sign in invasive pulmonary mucormycosis: a rare case report. *Diagn Pathol* 2013;8:82.
55. Stewart JI, D'Alonzo GE, Ciccolella DE, Patel NB, Durra H, Clauss

- HE. Reverse halo sign on chest imaging in a renal transplant recipient. *Transpl Infect Dis* 2014;16(1):115-118.
56. Suzuki K, Seyama K, Hayashi T, Yamashiro Y, Shiraishi A, Kuwatsuru R. Reversed halo sign in tuberos sclerosis complex. *Case Rep Radiol* 2013;2013:428501.
57. Yükksekaya R, Çelikyay F, Yılmaz A, İnönü H, Köseoğlu D, Sade R. Reversed halo sign in hypersensitivity pneumonia: a diagnostic difficulty. *Respir Case Rep* 2013;2(3):112-116.
58. Zhan X, Wang Z, Zhang L, Jin ML, Liu M, Chen WH, Dai HP. Clinical and pathological features of adult pulmonary tuberculosis with reversed halo sign. *Int J Tuberc Lung Dis* 2013;17(12):1621-1625.
59. Moon S, Ryu YH, Kim S, Choe KO, Lee J, Sung K. Reversed halo sign: a new supplementary CT finding in confident diagnosis of BOOP. *Radiology* 2000;217(S):335.
60. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. *Radiology* 2008;246(3):697-722.
61. Marom EM, Kontoyiannis DP. Imaging studies for diagnosing invasive fungal pneumonia in immunocompromised patients. *Curr Opin Infect Dis* 2011;24(4):309-314.
62. Georgiadou SP, Sipsas NV, Marom EM, Kontoyiannis DP. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. *Clin Infect Dis* 2011;52(9):1144-1155.
63. Marchiori E, Zanetti G, Irion KL, Nobre LF, Hochhegger B, Mançano AD, Escuissato DL. Reversed halo sign in active pulmonary tuberculosis: criteria for differentiation from cryptogenic organizing pneumonia. *AJR Am J Roentgenol* 2011;197(6):1324-1327.
64. Marchiori E, Zanetti G, Hochhegger B, Irion KL. Re: Reversed halo sign: nodular wall as criterion for differentiation between cryptogenic organizing pneumonia and active granulomatous diseases. *Clin Radiol* 2010;65(9):770-771.
65. Marchiori E, Marom EM, Zanetti G, Hochhegger B, Irion KL, Godoy MC. Reversed halo sign in invasive fungal infections: criteria for differentiation from organizing pneumonia. *Chest* 2012;142(6):1469-1473.